The purpose of this study is to find out about the safety and tolerability of IMP4297 in combination with temozolomide to determine if it is an effective treatment for solid tumors. IMP4297 is experimental, which means it is not approved by Health Authorities including the U.S. Food and Drug Administration (FDA) for the treatment of solid tumors. Temozolomide is a chemotherapy drug that is approved by the FDA for the treatment of brain cancer.
Are age 18 and older
Have been diagnosed with Extensive Stage Small Cell Lung Cancer
Have received one and only one course of 1L standard platinum-based therapy
There are 5 study periods: screening, treatment, end of treatment, safety follow-up, and survival follow-up. All aspects of your participation will take place at the study location or at your place of residence.
You will receive both IMP4297 and Temozolomide daily by mouth.
During the study, you may have tests to assess:
Follow the study staff’s directions regarding the study
Yes, you will receive $150 upon your completion of the screening visit and $50 for each subsequent visit.